Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substiuted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 ?m sieve and to methods of making the same.

Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

Abstract: Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptavidin. In certain embodiments, the compositions further comprise a diagnostic agent.

Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Abstract: A dispenser for dispensing one or more dry-powder inhaler devices, having at least one compartment configured to hold at least one dry-powder inhaler device, the at least one dry-powder inhaler device comprising a casing enclosing at least one compartment containing an inhalable medicament covered by a cover, and at least one puncture mechanism comprising at least one pin structure operably aligned with the at least one compartment, and at least one obstruction internally located within the dispenser and adjacent to an opening, wherein, upon a dry-powder inhaler device being pulled from a dispenser, the at least one obstruction is configured to actuate the at least one puncture mechanism to extend the at least one pin structure into the casing, thereby puncturing the cover of the at least one compartment.

Abstract: A dry-powder inhalation device including a casing having at least one push button located on an external portion thereof, the push button including at least one pin structure, an air inlet located at a first terminus of the casing; a powder delivery port located at a second terminus of the casing and is positioned distal to the air inlet; and an elongated support panel located within an interior of the casing and being fitted within the casing so as to partially rotate therein about a single axis. The support panel has at least one compartment containing dry-powder located proximal to the first terminus, and the at least one pin structure is located proximal to the air inlet and arranged above the dry-powder compartment.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substiuted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: An improved dry-powder inhalation device having a casing having an air inlet located at a first terminus; a powder delivery port located at a second terminus, which is positioned distal to the air inlet; and an elongated support panel located within an interior of the casing and being fitted within the casing so as to partially rotate therein about a single axis. The casing has at least one compartment containing dry-powder located proximally to the second terminus, and the support panel has a plurality of needle-like structures located proximal to the delivery port and arranged opposite the dry-powder compartment. The compartment with a dry-powder includes a cover encasing the dry-powder, whereby airflow through the device causes the elongated support panel to partially rotate repeatedly within the casing, whereby the plurality of needle-like structures strike the covered compartment, causing the dry-powder to be released into the airflow.

Abstract: The invention provides cardiovascular imaging agents comprising an anticoagulant (e.g., dabigatran derivatives) with a label (e.g., radiolabeled, fluorinated or radiofluorinated). Methods for using the cardiovascular imaging agents and kits containing the cardiovascular imaging agents or components suitable for production of the cardiovascular imaging agents are also provided.

Abstract: A dry-powder inhalation device including a casing having at least one push button located on an external portion thereof, the push button including at least one pin structure, an air inlet located at a first terminus of the casing; a powder delivery port located at a second terminus of the casing and is positioned distal to the air inlet; and an elongated support panel located within an interior of the casing and being fitted within the casing so as to partially rotate therein about a single axis. The support panel has at least one compartment containing dry-powder located proximal to the first terminus, and the at least one pin structure is located proximal to the air inlet and arranged above the dry-powder compartment.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: An improved dry-powder inhalation device having a casing having an air inlet located at a first terminus; a powder delivery port located at a second terminus, which is positioned distal to the air inlet; and an elongated support panel located within an interior of the casing and being fitted within the casing so as to partially rotate therein about a single axis. The support panel has at least one compartment containing dry-powder located proximally to the second terminus, and the casing has a plurality of needle-like structures located proximal to the delivery port and arranged above the dry-powder compartment. The compartment with a dry-powder includes a blister structure encasing the dry-powder, whereby airflow through the device causes the elongated support panel to partially rotate repeatedly within the casing, thereby striking the plurality of needle-like structures and releasing the dry-powder in the airflow.